Voyager Therapeutics, Inc. (VYGR)

Voyager Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	65.3	71.37	68.8	98.96	117.43
Short-Term Investments	131.15	195.32	162.07	19.89	15.11
Cash & Short-Term Investments	196.45	266.68	230.88	118.85	132.54
Cash Growth	-26.34%	15.51%	94.26%	-10.33%	-26.83%
Accounts Receivable	1.91	2.18	83.49	0.26	0.73
Other Current Assets	4.33	7.95	5.32	5.39	3.43
Total Current Assets	202.69	276.81	319.68	124.5	136.7
Net Property, Plant & Equipment	41.61	47.66	30	33.34	55.38
Long-Term Investments	5.24	65.7	-	-	-
Other Long-Term Assets	2.74	2.87	1.59	1.52	1.78
Total Assets	252.28	393.05	351.28	159.36	193.86
Accounts Payable	5.01	4	1.6	2.57	0.57
Accrued Expenses	12.1	14.17	16.82	7.82	10.95
Current Portion of Leases	7.84	7.23	3.2	-	-
Unearned Revenue	1.59	24.39	42.88	59.38	33.89
Other Current Liabilities	-	-	-	2.83	5.57
Total Current Liabilities	26.54	49.79	64.51	72.59	50.98
Long-Term Leases	28.66	36.5	17.09	-	-
Other Long-Term Liabilities	1	7	33.36	27.75	47.82
Total Long-Term Liabilities	29.66	43.5	50.45	27.75	47.82
Total Liabilities	56.2	93.29	114.96	100.34	98.8
Common Stock	0.06	0.06	0.04	0.04	0.04
Additional Paid-in Capital	641.9	626.3	497.51	452.71	442.26
Accumulated Other Comprehensive Income	0.03	-0.41	-0.05	-0.22	-0.14
Retained Earnings	-445.91	-326.18	-261.18	-393.51	-347.1
Shareholders' Equity	196.08	299.76	236.32	59.02	95.06
Total Liabilities & Equity	252.28	393.05	351.28	159.36	193.86
Total Debt	36.5	43.73	20.29	0	0
Net Cash (Debt)	159.95	222.96	210.58	118.85	132.54
Net Cash Growth	-28.26%	5.88%	77.19%	-10.33%	-26.83%
Net Cash Per Share	2.72	3.87	4.72	3.10	3.52
Book Value	196.08	299.76	236.32	59.02	95.06
Book Value Per Share	3.33	5.20	5.30	1.54	2.52
Tangible Book Value	196.08	299.76	236.32	59.02	95.06
Tangible Book Value Per Share	3.33	5.20	5.30	1.54	2.52

Updated Mar 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q